Sigma-1 Receptor Stimulation with PRE-084 Ameliorates Myocardial Ischemia-Reperfusion Injury in Rats

Overview

Journal Chin Med J (Engl)

Specialty General Medicine

Date 2018 Feb 28

PMID 29483387

Citations 9

Authors

Qi-Jun Gao

Bo Yang

Jing Chen

Shao-Bo Shi

Hong-Jie Yang

Xin Liu

Affiliations

Soon will be listed here.

Abstract

Background: The sigma receptors are a relatively novel receptor group with respect to knowledge of their effect on health. Although the sigma-1 receptor agonist PRE-084 exhibits a cardioprotective effect in some studies, the benefits in cases of myocardial ischemia/reperfusion (I/R) are not clear. The aim of this study was to explore the mechanism of action and assess the effect of PRE-084 on myocardial I/R injury in rats.

Methods: In this study, rats were assigned randomly to three groups with computer (n = 14 for each group): a sham group, an I/R group, and a PRE-084 group. In the PRE-084 group, rats were administered PRE-084 1 h before operation. In the myocardial I/R model, the left anterior descending branch of rats was ligated and opened half an hour later. Cardiac function was assessed, and the apoptosis index was evaluated. The mechanisms of the cardioprotective effects of PRE-084 were explored.

Results: PRE-084 pretreatment preserved cardiac function and reduced myocardial apoptosis (F = 86.0, P < 0.01) with Western blotting analysis, showing significantly reduced expression of Bax (F = 75.7, P < 0.01) and cleaved-caspase 3 (F = 44.7, P < 0.01), along with increased expression of the Bcl-2 protein (P < 0.01) and phosphorylated protein kinase B (p-Akt) (P < 0.01) and phosphorylated-endothelial nitric oxide synthase (p-eNOS; P < 0.01).

Conclusion: PRE-084 preserved cardiac function and reduced myocardial apoptosis through the activation of Akt and eNOS.

Citing Articles

Sigma-1 Receptor Specific Biological Functions, Protective Role, and Therapeutic Potential in Cardiovascular Diseases.

Almaamari A, Sultan M, Zhang T, Qaed E, Wu S, Qiao R Cardiovasc Toxicol. 2025; 25(4):614-630.

PMID: 39937319 DOI: 10.1007/s12012-025-09975-5.

Sigma-1 Receptor Signaling: In Search of New Therapeutic Alternatives for Cardiovascular and Renal Diseases.

Munguia-Galaviz F, Miranda-Diaz A, Cardenas-Sosa M, Echavarria R Int J Mol Sci. 2023; 24(3).

PMID: 36768323 PMC: 9916216. DOI: 10.3390/ijms24031997.

Effects of sub-chronic, in vivo administration of sigma-1 receptor ligands on platelet and aortic arachidonate cascade in streptozotocin-induced diabetic rats.

Vaczi S, Barna L, Laczi K, Tomosi F, Rakhely G, Penke B PLoS One. 2022; 17(11):e0265854.

PMID: 36395179 PMC: 9671357. DOI: 10.1371/journal.pone.0265854.

Unfolding the cardioprotective potential of sigma-1 receptor-directed molecular imaging.

Higuchi T, Werner R J Nucl Cardiol. 2022; 30(2):662-664.

PMID: 35927376 PMC: 10125936. DOI: 10.1007/s12350-022-03077-3.

Chronic Sigma 1 receptor activation alleviates right ventricular dysfunction secondary to pulmonary arterial hypertension.

Sun Y, Wan W, Zhao X, Han X, Ye T, Chen X Bioengineered. 2022; 13(4):10843-10856.

PMID: 35473584 PMC: 9208487. DOI: 10.1080/21655979.2022.2065953.

References

Keeley E, Boura J, Grines C . Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003; 361(9351):13-20. DOI: 10.1016/S0140-6736(03)12113-7. View

Salas M, Valverde C, Sanchez G, Said M, Rodriguez J, Portiansky E . The signalling pathway of CaMKII-mediated apoptosis and necrosis in the ischemia/reperfusion injury. J Mol Cell Cardiol. 2010; 48(6):1298-306. PMC: 2866824. DOI: 10.1016/j.yjmcc.2009.12.015. View

Hernandez-Resendiz S, Palma-Flores C, De Los Santos S, Roman-Anguiano N, Flores M, de la Pena A . Reduction of no-reflow and reperfusion injury with the synthetic 17β-aminoestrogen compound Prolame is associated with PI3K/Akt/eNOS signaling cascade. Basic Res Cardiol. 2015; 110(2):1. DOI: 10.1007/s00395-015-0464-y. View

Dorn 2nd G . Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling. Cardiovasc Res. 2008; 81(3):465-73. PMC: 2721651. DOI: 10.1093/cvr/cvn243. View

Tagashira H, Bhuiyan S, Shioda N, Hasegawa H, Kanai H, Fukunaga K . Sigma1-receptor stimulation with fluvoxamine ameliorates transverse aortic constriction-induced myocardial hypertrophy and dysfunction in mice. Am J Physiol Heart Circ Physiol. 2010; 299(5):H1535-45. DOI: 10.1152/ajpheart.00198.2010. View

Hausenloy D, Yellon D . New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res. 2004; 61(3):448-60. DOI: 10.1016/j.cardiores.2003.09.024. View

Wagner C, Tillack D, Simonis G, Strasser R, Weinbrenner C . Ischemic post-conditioning reduces infarct size of the in vivo rat heart: role of PI3-K, mTOR, GSK-3beta, and apoptosis. Mol Cell Biochem. 2010; 339(1-2):135-47. DOI: 10.1007/s11010-009-0377-x. View

Rousseaux C, Greene S . Sigma receptors [σRs]: biology in normal and diseased states. J Recept Signal Transduct Res. 2015; 36(4):327-388. PMC: 4906365. DOI: 10.3109/10799893.2015.1015737. View

Zhao M, Yang J, Wang X, Tang C, Du J, Jin H . The PI3K/Akt pathway mediates the protection of SO(2) preconditioning against myocardial ischemia/reperfusion injury in rats. Acta Pharmacol Sin. 2013; 34(4):501-6. PMC: 4002792. DOI: 10.1038/aps.2012.204. View

10.

Sun Y, Jiang C, Jiang J, Qiu L . Dexmedetomidine protects mice against myocardium ischaemic/reperfusion injury by activating an AMPK/PI3K/Akt/eNOS pathway. Clin Exp Pharmacol Physiol. 2017; 44(9):946-953. DOI: 10.1111/1440-1681.12791. View

11.

Hayashi T . Sigma-1 receptor: the novel intracellular target of neuropsychotherapeutic drugs. J Pharmacol Sci. 2015; 127(1):2-5. DOI: 10.1016/j.jphs.2014.07.001. View

12.

McCully J, Wakiyama H, Hsieh Y, Jones M, Levitsky S . Differential contribution of necrosis and apoptosis in myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2004; 286(5):H1923-35. DOI: 10.1152/ajpheart.00935.2003. View

13.

Heusch G . Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res. 2015; 116(4):674-99. DOI: 10.1161/CIRCRESAHA.116.305348. View

14.

Penumathsa S, Thirunavukkarasu M, Koneru S, Juhasz B, Zhan L, Pant R . Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat. J Mol Cell Cardiol. 2006; 42(3):508-16. PMC: 1857339. DOI: 10.1016/j.yjmcc.2006.10.018. View

15.

Hatok J, Racay P . Bcl-2 family proteins: master regulators of cell survival. Biomol Concepts. 2016; 7(4):259-70. DOI: 10.1515/bmc-2016-0015. View

16.

White E . Life, death, and the pursuit of apoptosis. Genes Dev. 1996; 10(1):1-15. DOI: 10.1101/gad.10.1.1. View

17.

Chiong M, Wang Z, Pedrozo Z, Cao D, Troncoso R, Ibacache M . Cardiomyocyte death: mechanisms and translational implications. Cell Death Dis. 2011; 2:e244. PMC: 3252742. DOI: 10.1038/cddis.2011.130. View

18.

Faubel S, Edelstein C . Caspases as drug targets in ischemic organ injury. Curr Drug Targets Immune Endocr Metabol Disord. 2005; 5(3):269-87. DOI: 10.2174/1568008054863754. View

19.

He F, Xu B, Chen C, Jia H, Wu J, Wang X . Methylophiopogonanone A suppresses ischemia/reperfusion-induced myocardial apoptosis in mice via activating PI3K/Akt/eNOS signaling pathway. Acta Pharmacol Sin. 2016; 37(6):763-71. PMC: 4954762. DOI: 10.1038/aps.2016.14. View

20.

Ibanez B, Heusch G, Ovize M, Van de Werf F . Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol. 2015; 65(14):1454-71. DOI: 10.1016/j.jacc.2015.02.032. View